search
Back to results

UVB Model Validation Study

Primary Purpose

Pain, Inflammation, Healthy Volunteers

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
Ibuprofen, Hydrocortisone
Hydrocortisone
Sponsored by
X-pert Med GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Pain focused on measuring UVB, pain, inflammation, model, healthy volunteers, Ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • healthy volunteers

Exclusion Criteria:

-

Sites / Locations

  • X-pert Med GmbH

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Group A

Group B

Arm Description

Ibuprofen 600 mg (active comparator); Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)

Oral Placebo (placebo comparator), Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)

Outcomes

Primary Outcome Measures

Hyperalgesia to heat

Secondary Outcome Measures

Erythema, Skin temperature

Full Information

First Posted
January 22, 2010
Last Updated
July 12, 2010
Sponsor
X-pert Med GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT01055249
Brief Title
UVB Model Validation Study
Official Title
Single Centre, Subject and Observer Blinded, Placebo Controlled, Cross-over Study of the Effect of Oral Ibuprofen and Topical Hydrocortisone-21-acetate on Ultraviolet Radiation (UVR) Induced Pain and Inflammation in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
July 2010
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
X-pert Med GmbH

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Single centre, subject and observer blinded, placebo controlled, cross-over study of the effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers conducted in two segments and using an intra-individual comparison of application areas.
Detailed Description
Single centre, subject and observer blinded, placebo controlled, cross-over study of the effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers conducted in two segments and using an intra-individual comparison of application areas. Subjects that signed the informed consent and are eligible to the study will be irradiated on the back to evaluate their individual minimal erythema doses (MEDs). Read out to determine MED will be done within 24 h after UVR. A training session (without study medication) using the MED definition areas will be performed in order to introduce subjects to the testing and rating procedures. Subjects will come in within 14 days of screening to start the first Segment of the study. Eligible subjects will be randomised to receive either: IB 600 mg, applied orally b.i.d., or OP, applied orally b.i.d. Allocation of topical treatment to these areas will be randomly assigned to: PG, 15 μl/cm2 applied topically b.i.d., or HC, 15 μl/cm2 applied topically b.i.d. Defined areas will be irradiated with defined dosages of UVR. Assessment of hyperalgesia to heat and signs of inflammation (erythema, skin temperature) for all areas will be performed. Subjects return within 4 to 11 days to the study site for the second segment of the study. Treatment allocation will be crossed-over and new treatment areas will be selected on the back.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Inflammation, Healthy Volunteers
Keywords
UVB, pain, inflammation, model, healthy volunteers, Ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Other
Arm Description
Ibuprofen 600 mg (active comparator); Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
Arm Title
Group B
Arm Type
Other
Arm Description
Oral Placebo (placebo comparator), Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
Intervention Type
Drug
Intervention Name(s)
Ibuprofen, Hydrocortisone
Intervention Description
Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
Intervention Type
Drug
Intervention Name(s)
Hydrocortisone
Intervention Description
Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
Primary Outcome Measure Information:
Title
Hyperalgesia to heat
Time Frame
72 h
Secondary Outcome Measure Information:
Title
Erythema, Skin temperature
Time Frame
72 h

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: healthy volunteers Exclusion Criteria: -
Facility Information:
Facility Name
X-pert Med GmbH
City
Graefelfing
State/Province
Bavaria
ZIP/Postal Code
82166
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

UVB Model Validation Study

We'll reach out to this number within 24 hrs